The aim of this webinar is to revisit latest evidence on secondary preventive effect of SGLT2 inhibitor drugs.
The key learning objectives will be;
- To discuss the cardioprotective effects of SGLT2 inhibitors in terms of heart failure.
- To discuss the effect of SGLT2 inhibitors on kidney function
Program /agenda
| Introduction | |
| WelcomeLearning objectivesIntro/Bio Speakers | Dr. Samuel Seidu, chair (U.K.) |
| Heart failure and SGLT2 inhibitor therapy beyond the presence of diabetes | Dr. Xavier Garcia Moll (ES) |
| SGLT2 inhibitors and the kidney: matter of controversy | Dr.David Wheeler (UK) |
| Question and answers | All |